This research study is studying a drug combination as a possible treatment for endometrial
The drugs involved in this study are:
mirvetuximab soravtansine (IMGN853)
This research study is a Phase II clinical trial. Phase II clinical trials test the safety
and effectiveness of an investigational drug to learn whether the drug works in treating a
specific disease. "Investigational" means that the drug is being studied.
The FDA (the U.S. Food and Drug Administration) has not approved mirvetuximab soravtansine as
a treatment for any disease.
The FDA (the U.S. Food and Drug Administration) has not approved pembrolizumab for this
specific disease but it has been approved for other uses.
In this research study, the investigators are studying the combination of mirvetuximab
soravtansine and pembrolizumab. Pembrolizumab is an immunotherapy that activates a patient's
own immune system to recognize and kill tumor cells. Pembrolizumab by itself may not be
enough to kill cancer cells in all people with cancer. In this study, all patients will
receive mirvetuximab soravtansine and pembrolizumab. Mirvetuximab soravtansine is an
antibody-drug conjugate. That is a type of agent that attaches a chemotherapy drug to a
molecule that binds a protein on the outside of cancer cells. The protein targeted by
mirvetuximab soravtansine is called folate receptor-alpha (FRα). FRα is expressed on the
surface of certain cancers, including endometrial cancer cells. Mirvetuximab soravtansine is
expected to kill cancer cells by delivering chemotherapy to cells that have high levels of
FRα. To participate in this study, a sample of your tumor was previously tested, and was
found to have high levels of FRα. Mirvetuximab soravtansine also may also active immune cells
and improve the response to immunotherapies like pembrolizumab.
In this study, the investigators expect to learn whether the combination of pembrolizumab and
mirvetuximab soravtansine can shrink endometrial cancers or prevent their growth for at least
6 months. The investigators will also learn more about the side effects patients experience
who receive this treatment. The investigators also plan to learn more about which patients
are likely to benefit from this treatment
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.